Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03536884
Registration number
NCT03536884
Ethics application status
Date submitted
14/05/2018
Date registered
25/05/2018
Date last updated
28/09/2023
Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Query!
Scientific title
A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Query!
Secondary ID [1]
0
0
2017-003784-35
Query!
Secondary ID [2]
0
0
PS0015
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
BE RADIANT
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Chronic Plaque Psoriasis
0
0
Query!
Moderate to Severe Chronic Plaque Psoriasis
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Bimekizumab
Treatment: Drugs - Secukinumab
Other interventions - Placebo
Experimental: Bimekizumab dosage regimen 1 - Subjects randomized to this arm will receive bimekizumab dosage regimen 1 (BKZ 1).
At Week 16 subjects will be re-randomized and continue to receive BKZ 1 or to switch to bimekizumab regimen 2 (BKZ 2).
Placebo will be administered at pre-specified time-points to maintain the blinding over the double-blind Treatment Period.
Subjects allowed to enroll in the open-label extension (OLE) Period will receive BKZ 1 or BKZ 2. Subjects will switch from BKZ 1 to BKZ 2 at Week 64 or at the next scheduled Visit.
Eligible subjects who completed OLE, have entered Safety Follow Up (SFU) or completed SFU would start OLE2 on BKZ 1 before switching to BKZ 2 after 16 weeks or start OLE2 on BKZ 2.
Experimental: Bimekizumab dosage regimen 2 - Subjects randomized to this arm will receive bimekizumab dosage regimen 2 (BKZ 2) starting at Week 16 after initial treatment on bimekizumab regimen 1 (BKZ 1) for 16 weeks.
Placebo will be administered at pre-specified time-points to maintain the blinding over the double-blind Treatment Period.
Subjects allowed to enroll in the open-label extension (OLE) Period will receive BKZ 1 or BKZ 2. Subjects will switch from BKZ 1 to BKZ 2 at Week 64 or at the next scheduled Visit.
Eligible subjects who completed OLE, have entered SFU or completed SFU would start OLE2 on BKZ 1 before switching to BKZ 2 after 16 weeks or start OLE2 on BKZ 2.
Active Comparator: Secukinumab - Subjects will receive secukinumab. Subjects allowed to enroll in the open-label extension (OLE) Period will be re-randomized to receive bimekizumab dosage regimen 1 (BKZ 1) or bimekizumab dosage regimen 2 (BKZ 2).
Eligible subjects who completed OLE, have entered SFU or completed SFU would start OLE2 on BKZ 1 before switching to BKZ 2 after 16 weeks or start OLE2 on BKZ 2.
Treatment: Drugs: Bimekizumab
Subjects will receive bimekizumab at pre-specified time-points.
Treatment: Drugs: Secukinumab
Subjects will receive secukinumab at pre-specified time-points.
Other interventions: Placebo
Subjects will receive placebo at pre-specified time-points to maintain the blinding in the double-blind Treatment Period.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With a Psoriasis Area and Severity Index 100 (PASI100) Response at Week 16
Query!
Assessment method [1]
0
0
The PASI100 response assessments are based on 100% improvement in PASI score from Baseline. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
Query!
Timepoint [1]
0
0
Week 16
Query!
Secondary outcome [1]
0
0
Percentage of Participants With a PASI75 Response at Week 4
Query!
Assessment method [1]
0
0
The PASI75 response assessments are based on at least 75% improvement in PASI score from Baseline. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for redness, thickness, and scaling for each of the 4 body areas with score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of body areas and converting to 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
Query!
Timepoint [1]
0
0
Week 4
Query!
Secondary outcome [2]
0
0
Percentage of Participants With a PASI90 Response at Week 16
Query!
Assessment method [2]
0
0
The PASI90 response assessments are based on at least 90% improvement in PASI score from Baseline. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for redness, thickness, and scaling for each of the 4 body areas with score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI=average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
Query!
Timepoint [2]
0
0
Week 16
Query!
Secondary outcome [3]
0
0
Percentage of Participants With a PASI100 Response at Week 48
Query!
Assessment method [3]
0
0
The PASI100 response assessments are based on 100% improvement in PASI score from Baseline. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
Query!
Timepoint [3]
0
0
Week 48
Query!
Secondary outcome [4]
0
0
Percentage of Participants With a Investigator´s Global Assessment (IGA) Response (0/1) at Week 16
Query!
Assessment method [4]
0
0
The IGA measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as Clear (0) or Almost Clear (1) with at least a two-category improvement from Baseline at Week 16.
Query!
Timepoint [4]
0
0
Week 16
Query!
Secondary outcome [5]
0
0
Number of Treatment-emergent Adverse Events (TEAEs) Adjusted by Duration of Participant Exposure to Investigational Medicinal Product (IMP) From Baseline up to Week 48
Query!
Assessment method [5]
0
0
The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
Query!
Timepoint [5]
0
0
From Baseline up to Week 48
Query!
Secondary outcome [6]
0
0
Number of Serious Adverse Events (SAEs) Adjusted by Duration of Participant Exposure to IMP From Baseline up to Week 48
Query!
Assessment method [6]
0
0
The number of SAEs adjusted by duration of exposure to study treatment was scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
Query!
Timepoint [6]
0
0
From Baseline up to Week 48
Query!
Secondary outcome [7]
0
0
Number of TEAEs Leading to Withdrawal Adjusted by Duration of Participant Exposure to IMP From Baseline up to Week 48
Query!
Assessment method [7]
0
0
The number of TEAEs leading to discontinuation adjusted by duration of exposure to study treatment was scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
Query!
Timepoint [7]
0
0
From Baseline up to Week 48
Query!
Eligibility
Key inclusion criteria
Double-blind Treatment Period
- Male or female at least 18 years of age
- Subject must have had chronic plaque psoriasis (PSO) for at least 6 months prior to
the Screening visit
- Subject must have Psoriasis Area Severity Index (PASI) >=12 and body surface area
(BSA) affected by PSO >=10% and Investigator's Global Assessment (IGA) score >=3 on a
5 point scale
- Subject must be a candidate for systemic PSO therapy and/or phototherapy
- Subject must be considered, in the opinion of the Investigator, to be a suitable
candidate for treatment with secukinumab per regional labeling and has no
contraindications to receive secukinumab as per the local label
- Female subject of childbearing potential must be willing to use highly effective
method of contraception
Open-label extension (OLE) Period
- Completed the double-blind Treatment Period without meeting any withdrawal criteria
- All Week 48 visit assessments completed
- Compliant with ongoing clinical study requirements
- Signed a separate OLE Period Informed Consent Form (ICF)
- Female subject of childbearing potential must be willing to use highly effective
method of contraception
OLE2 Period (USA and Canada)
- Completed the OLE Period without meeting any withdrawal criteria
- Compliant with ongoing clinical study requirements
- Female subject of childbearing potential must be willing to use highly effective
method of contraception
- Subjects with a diagnosis of Crohn's disease or ulcerative colitis are allowed as long
as they have no active symptomatic disease (US only)
- Signed a separate OLE2 Period ICF
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Double-blind Treatment Period
- Subject has an active infection (except common cold), a serious infection, or a
history of opportunistic, recurrent or chronic infections
- Subject has concurrent acute or chronic viral hepatitis B or C or human
immunodeficiency virus (HIV) infection
- Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB
infection, or has current or history of nontuberculous mycobacterium (NTMB) infection
- Subject has any other condition, including medical or psychiatric, which, in the
Investigator's judgment, would make the subject unsuitable for inclusion in the study
- Presence of active suicidal ideation or severe depression
- Subject has any active malignancy or history of malignancy within 5 years prior to the
Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell
carcinoma, or in situ cervical cancer
OLE2 Period (USA and Canada)
- Subject has developed any medical or psychiatric condition, which, in the
Investigator's judgment, would make the subject unsuitable for inclusion in OLE2
Period
- Subject had a positive or indeterminate interferon-gamma release assay (IGRA) in the
OLE study to Week 144, unless appropriately evaluated and treated
- Presence of active suicidal ideation or severe depression
- Subject has developed any active malignancy or history of malignancy prior to the OLE2
Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell
carcinoma, or in situ cervical cancer
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
13/06/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
9/08/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
743
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
PS0015 3 - Carlton
Query!
Recruitment hospital [2]
0
0
PS0015 7 - Hectorville
Query!
Recruitment hospital [3]
0
0
PS0015 6 - Kogarah
Query!
Recruitment hospital [4]
0
0
Ps0015 11 - Parkville
Query!
Recruitment hospital [5]
0
0
PS0015 9 - Woolloongabba
Query!
Recruitment postcode(s) [1]
0
0
- Carlton
Query!
Recruitment postcode(s) [2]
0
0
- Hectorville
Query!
Recruitment postcode(s) [3]
0
0
- Kogarah
Query!
Recruitment postcode(s) [4]
0
0
- Parkville
Query!
Recruitment postcode(s) [5]
0
0
- Woolloongabba
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Iowa
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Louisiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Missouri
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New Hampshire
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New York
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
North Carolina
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Ohio
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Oregon
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
Belgium
Query!
State/province [15]
0
0
Brussels
Query!
Country [16]
0
0
Belgium
Query!
State/province [16]
0
0
Bruxelles
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Liege
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Halifax
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Hamilton
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Mississauga
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Peterborough
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Richmond Hill
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Toronto
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Waterloo
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Toulouse
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Augsburg
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Berlin
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Hamburg
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Lübeck
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Mahlow
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Mainz
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
München
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Münster
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Neu-ulm
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Tuebingen
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Witten
Query!
Country [37]
0
0
Netherlands
Query!
State/province [37]
0
0
Amsterdam
Query!
Country [38]
0
0
Netherlands
Query!
State/province [38]
0
0
Breda
Query!
Country [39]
0
0
Poland
Query!
State/province [39]
0
0
Bialystok
Query!
Country [40]
0
0
Poland
Query!
State/province [40]
0
0
Gdansk
Query!
Country [41]
0
0
Poland
Query!
State/province [41]
0
0
Katowice
Query!
Country [42]
0
0
Poland
Query!
State/province [42]
0
0
Krakow
Query!
Country [43]
0
0
Poland
Query!
State/province [43]
0
0
Lodz
Query!
Country [44]
0
0
Poland
Query!
State/province [44]
0
0
Ostrowiec Swietokrzyski
Query!
Country [45]
0
0
Poland
Query!
State/province [45]
0
0
Wroclaw
Query!
Country [46]
0
0
Spain
Query!
State/province [46]
0
0
Alicante
Query!
Country [47]
0
0
Spain
Query!
State/province [47]
0
0
Barcelona
Query!
Country [48]
0
0
Spain
Query!
State/province [48]
0
0
Madrid
Query!
Country [49]
0
0
Spain
Query!
State/province [49]
0
0
Sant Joan Despí
Query!
Country [50]
0
0
Turkey
Query!
State/province [50]
0
0
Gaziantep
Query!
Country [51]
0
0
Turkey
Query!
State/province [51]
0
0
Istanbul
Query!
Country [52]
0
0
Turkey
Query!
State/province [52]
0
0
Kayseri
Query!
Country [53]
0
0
United Kingdom
Query!
State/province [53]
0
0
Newcastle Upon Tyne
Query!
Country [54]
0
0
United Kingdom
Query!
State/province [54]
0
0
Salford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
UCB Biopharma SRL
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with
moderate to severe chronic plaque psoriasis (PSO).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03536884
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
UCB Cares
Query!
Address
0
0
001 844 599 2273
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03536884
Download to PDF